{"id":555143,"date":"2026-04-20T01:00:00","date_gmt":"2026-04-19T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/si-los-antihistaminicos-no-son-suficientes-y-los-niveles-de-ige-son-bajos\/"},"modified":"2026-04-23T13:31:48","modified_gmt":"2026-04-23T11:31:48","slug":"si-los-antihistaminicos-no-son-suficientes-y-los-niveles-de-ige-son-bajos","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/si-los-antihistaminicos-no-son-suficientes-y-los-niveles-de-ige-son-bajos\/","title":{"rendered":"Si los antihistam\u00ednicos no son suficientes y los niveles de IgE son bajos"},"content":{"rendered":"\n<p><strong>La urticaria cr\u00f3nica suele conllevar un alto nivel de sufrimiento, pero hay nuevas opciones de tratamiento en camino: han ocurrido muchas cosas desde la publicaci\u00f3n de la actual directriz S3. El dupilumab es otro biol\u00f3gico que ha recibido la aprobaci\u00f3n de la FDA\/EMA para la UCE, pero s\u00f3lo para pacientes no tratados con omalizumab. El remibrutinib, una mol\u00e9cula peque\u00f1a, tambi\u00e9n ha superado los obst\u00e1culos de la aprobaci\u00f3n en EE.UU. y se dispone de nuevos datos sobre los biol\u00f3gicos barzolvolimab y briquilimab. La IgE total es cada vez m\u00e1s importante como biomarcador predictivo para seleccionar la terapia sist\u00e9mica de primera l\u00ednea adecuada.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fsi-los-antihistaminicos-no-son-suficientes-y-los-niveles-de-ige-son-bajos%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>La urticaria cr\u00f3nica suele conllevar un alto nivel de sufrimiento, pero hay nuevas opciones de tratamiento en camino: han ocurrido muchas cosas desde la publicaci\u00f3n de la actual directriz S3&#8230;.&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fsi-los-antihistaminicos-no-son-suficientes-y-los-niveles-de-ige-son-bajos%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":555144,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Urticaria cr\u00f3nica: nuevas alternativas terap\u00e9uticas a la vista  ","footnotes":"[{\"content\":\"Por ejemplo, autoinmunidad de tipo I (autoalergia), IgE contra autoant\\u00edgenos y autoinmunidad de tipo IIb con autoanticuerpos activadores de mastocitos.\",\"id\":\"dbf840d8-1aae-45dd-b6a5-76477ae2aa5f\"}]"},"category":[11298,11310,11483,11475,11408,11552],"tags":[91580,14913,13573,13562,84809,72047,91579],"powerkit_post_featured":[],"class_list":["post-555143","post","type-post","status-publish","format-standard","has-post-thumbnail","category-alergologia-e-inmunologia-clinica","category-dermatologia-y-venereologia","category-el-congreso-informa","category-estudios","category-farmacologia-y-toxicologia","category-rx-es","tag-alternativas-terapeuticas","tag-antihistaminico","tag-dupilumab-es","tag-omalizumab-es","tag-remibrutinib-es","tag-urticaria-cronica-es","tag-valores-de-ige","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-30 20:52:21","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/555143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=555143"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/555143\/revisions"}],"predecessor-version":[{"id":555145,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/555143\/revisions\/555145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/555144"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=555143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=555143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=555143"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=555143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}